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Regulation of renal EGF receptor expression is normal in Denys-Drash
syndrome. In patients with Denys-Drash syndrome, mutations of the
Wilms' tumor suppressor gene are associated with nephroblastomas and
developmental abnormalities of the genital tract and renal glomerulus.
Normally, the Wilms' tumor gene product (WT1) is expresscd at high
levels in visceral glomerular epithelial cells (VGEC) of the emerging fetal
glomerulus. We demonstrate that WTI could normally serve to suppress
EGF receptor expression in VGEC, since immunoreactive EGF receptor
is strikingly absent compared to epithelial cells of the emerging proximal
and distal tubule, which lack WTI. When HEK293 cells were en-
transfected with plasmids containing EGFR enhancer/promoter elements
linked to a CAT reporter and plasmids containing WT1 eDNA, EGFR
enhancer/promoter activity was suppressed by all wild-type WTI isoforms,
hut not by deletion mutants of WTI lacking normal zinc-finger or
N-terminal domains. Surprisingly, plasmids expressing a Denys-Drash
WTI mutant (R394W) retained the ability to suppress EGFR promoter
activity in this system. Furthermore, we found that immunoreactive EGFR
was appropriately undetectable in glomeruli from a three-year-old girl
with Denys-Drash syndrome and in sections of her Wilm's tumor. These
data suggest that faulty suppression of EGFR cannot account for the
abnormalities of glomerulogenesis seen in Denys-Drash patients.
Development of the human kidney begins at six weeks of fetal
age when the ureteric bud penetrates the metanephric blastema
and begins to undergo dichotymous branching. Adjacent to the tip
of each of its branches, small clusters of metanephric cells are
induced to condense into discrete vesicles and express new
transcription factors, including low levels of the Wilms' tumor
gene product (WT1). WTI is thought to play a critical role at this
early stage of nephrogenesis since transgenic mice with homozy-
gous inactivation of WTI are anephric.
As nephrogenesis proceeds, formation of a glomerulus at one
end of the S-shaped body involves a discrete set of epithelial cells
that contact the ingrowing capillary. These visceral glomerular
epithelial cells express high levels of the Wilms' tumor gene
product [1] and appear to discontinue proliferation; sister cells in
other segments of the S-shaped body lack WTI expression and
continue proliferating to form the massively elongated tubular
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sections of the nephron. WT1 appears to have a secondary
function that is critical to glomerulogenesis, since humans who are
heterozygous for certain mutations of WTI develop the Denys-
Drash syndrome, a uniform abnormality of glomerular develop-
ment associated with congenital nephrotic syndrome and mesan-
gial sclerosis [2, 3].
Recently, Englert et a! have shown that WT1 acts as a suppres-
sor of EGF receptor (EGFR) gene transcription in cultured
osteosarcoma (U2OS) cells [4]. If the observations regarding WT1
function in 020S cells are relevant to the developing kidney, it
would be expected that EGF receptor should be suppressed at
sites where WT1 expression is high, such as in the developing
glomerulus. Conversely, in settings such as the Denys-Drash
syndrome where the WT1 function is disturbed, dysregulated
EGFR transcription might contribute to abnormal glomerulogen-
esis. To explore the relationship between WTI and EGFR during
kidney development, we: (a) compared the effects of wild-type
(—I--) WT1 and the most common Denys-Drash WT1 mutant
(R394W) on EGFR promoter activity in a human fetal kidney
(HEK293) cell line; and (b) examined the pattern of immunore-
active EGFR expression in sections of normal human fetal kidney
and in renal tissue from a Denys-Drash patient.
METHODS
Materials
Dulbecco's Modified Eagle's Medium (DMEM) was obtained
from ICN Biomedicals Inc. (Costa Mesa, CA, USA), dialyzed
fetal bovine serum from Gibco BRL (Grand Island, NY, USA),
and trypsin-EDTA from Sigma Chemicals Co. (St. Louis, MO,
USA). Penicillin G and streptomycin were obtained from Marsam
Canada Pharmaceutical Inc. (Montreal, Qc, Canada). Polyclonal
rabbit anti-human WTI antibody (directed to amino acids 1-179)
was a gift of Dr. F. Rauscher III (The Wistar Institute, Philadel-
phia, PA, USA). Polyclonal rabbit anti-human EGFR (# sc-03)
raised to a peptide corresponding to amino acids 1005-1016 from
the cytoplasmic domain of the human receptor and blocking
peptide (# sc-03) to confirm antibody specificity were obtained
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Immunohistochemistry
Human fetal kidneys were obtained at the time of therapeutic
abortion with informed consent and approval of local hospital
ethics committees; foot length was used to estimate fetal age (FA;
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Fig. 1. Inverse relationship between WT1 (+) and EGFR (—) expression in GVEC of human fetal kidney. (A) Immunostaining for WTI (arrows) is
seen in epithelial cells of the vascular cleft of an S-shaped body (S) and in GVEC in a section of human fetal kidney (9 weeks fetal age). (B)
Immunostaining for EGFR is seen in cells of the proximal (P) and distal (D) tubules, but not in GVEC (arrow) of human fetal kidney (17 weeks fetal
age). Bar = 50 jm.
Fig. 6. EGFR immunostaining in a section of
renal tissue obtained from a three years-old
girl with Denys-Drash syndrome, obtained at
the time of Wilms' tumour removal. EGFR
immunostaining is absent from glomerular
epithelial cells (arrow) just as in sections of
normal human fetal kidney (Fig. 1). Note also
the absence of excessive VGEC proliferation in
the Drash glomerulus.
T'; -
' b.,
_- •t .
4. _. :t $I
,.
!1':.. -í
'a
_
;-.,• ••.:"'- •n,4 ' .. t
-'sft# r\t >• - •(. -•/
..: '•z: -"4,' - - 4
•
. -4-
-I. ' -
•55''-
''?
sifr • ,G
Mt
\•I . 1t
z
s_a.
•
• ).
8.5 to 20 weeks) [51. "Normal" renal tissue and adjacent Wilms'
tumor were also obtained from a three-year-old girl with complete
Denys-Drash syndrome involving gonadal dysgenesis, congenital
nephrotic syndrome, progressive renal insufficiency and unilateral
Wilms tumor. Tissue was fixed overnight in 4% paraformaldehyde
+ 0.2% glutaraldehyde (EGFR) or Bouin's fixative (WTI),
processed and embedded in paraffin. Sections 5 jsm thick were
mounted on poly-L-lysine coated slides (Sigma) and deparaf-
finized. The endogenous peroxidase activity was blocked by
incubation with 10% hydrogen peroxide for 20 minutes at 22°C.
Nonspecific binding was blocked with normal goat serum (5%)
and low fat milk protein (5%) in Tris-buffered saline (TBS) at
22°C for one hour. Sections were then incubated at 4°C with
anti-WTI antibody (1:300 to 500) or anti-EGFR antibody (1:400
to 600) overnight. The sections were washed three times with TBS
and incubated with the secondary biotinylated goat anti-rabbit
lgG (1:250 dilution) for 30 minutes at 22°C, followed by a one
hour incubation with Avidin-Biotin Peroxidase solution (Immu-
non, Pittsburgh, PA, USA). The bound peroxidase was visualized
using 0.025% 3,3'-diaminobenzidine diluted and developed by
addition of 0.02% (vol/vol) hydrogen peroxide solution (30%) for
one minute. Sections were counterstained with Mayers Hemalum.
For controls, primary anti-WT1 antibody was replaced by TBS
and anti-EGFR antibody was neutralized with a specific blocking
peptide (Santa Cruz Biotechnology).
'231-EGF binding assay
Specific high-affinity binding of 251-murine EGF (Amersham,
Oakville, ONT, Canada) to the cell surface was assayed as
previously described [6—8].
Transient co-tranfection assays
The human embryonic kidney cell line (HEK293), obtained
from ATCC (#CRL-1573), was maintained in Dulbecco's modi-
fled Eagle's medium supplemented with glutamine, penicillin!
streptomycin and 10% fetal bovine serum. For transient transfec-
tion assays, cells were detached and re-plated at a density of 8 to
10 x i0ji0 cm2 dish. After 24 hours, cell monolayers were
co-transfected overnight with calcium/phosphate precipitates con-
taining: (a) CMV/WT1 constructs (WTI expression vectors under
the control of the CMV promoter); (b) PERCAT2 (a vector in
which the human EGFR enhancer/promoter is fused to the
chioramphenicol acetyltransferase (CAT) reporter); (c) J3-galac-
tosidase expression vectors under the control of either CMV,
SV4O or RSV promoters. The total amount of CMV-driven
plasmid in each precipitate was kept constant (15 sg) by addition
of an empty CMV expression plasmid (CMV-delta). The medium
was changed after 18 hours, and freeze-thaw cell extracts were
prepared at 48 hours for CAT and p-galactosidase assays as
previously described [9]. The normal, splice variant and mutant
WT1 constructs are depicted in Figure 3 and have been described
elsewhere [10, 11]; PERCAT2 reporter plasmid was the generous
gift of Dr. Ira Pastan [12, 13].
RESULTS
EGFR immunohistochemistry in normal human fetal kidney
Sections of human fetal kidney (17 weeks fetal age) were
stained with polyclonal antibodies against WT1 or EGFR. Positive
staining for WT1 peptide is seen in the glomerular visceral
epithelial cells (GVEC) and their precursors in the cleft of
S-shaped bodies (Fig. 1A). EGFR is evident in proximal and distal
tubular epithelial cells and in glomerular mesangial or endothelial
cells, but it is entirely absent from GVEC (Fig. IB). EGFR
expression is known to be dramatically diminished in normal adult
kidney [7] and was barely detectable under these conditions with
our antibody (data not shown). The low levels of EGFR in adult
kidney have been identified by others using monoclonal antibod-
ies and an alkaline phosphatase-linked detection system [14]. To
confirm specificity of the EGFR antibody, a Western blot of total
proteins from cultured human fetal kidney cells was probed with
anti-hEGFR antibody (1:200); a single immunoreactive band was
detected at 180 kDa (Fig. 2). EGFR immunostaining in sections
of fetal kidney was completely eliminated by pre-incubation of
anti-EGFR with blocking peptide.
Characterization of HEK293 cells
HEK293 cells are well-suited for WTI/EGFR co-transfection
studies. The cells express a variety of epithelial markers including
cytokeratin and e-cadherin, but lack markers of highly differenti-
ated tubular cells such as alkaline phosphatase (data not shown).
They are efficiently transfected with the PERCAT2 reporter
plasmid, and, using an EGF binding assay, we were able to
demonstrate expression of normal endogenous EGF receptors at
the cell surface (21% of 1251-EGF specifically bound per mg
protein). Minimal levels of endogenous WT1 protein can be
detected by Western analysis in the untransfected HEK293 cells.
Co-transfection assays
CAT activity was readily detected in HEK293 cells transfected
with 4 ig of PERCAT2 (containing both the upstream enhancer
and 1.1 kb of the EGF promoter elements linked to CAT) (Fig. 3).
Dose-dependent inhibition of PERCAT2 (Fig. 4) activity was
observed when cells were co-transfected with the CMV!
WT1(—i—) expression plasmid. The inhibitory effect of CMV!
WT1(—!—) on the PERCAT construct was specific since activity
of CMV//3-galactosidase, SV4O!/3-galactosidase, RSV//3-galactosi-
dase or CMV/CAT control reporter vectors were not inhibited
when co-transfected with 2 jsg CMV!WT1 (—!—). In fact, activity
of all three -galactosidase vectors was indirectly stimulated in the
presence of WTI, exaggerating the inhibitory effects of WTI on
other targets if normalized for f3-galactosidase (data not shown).
For this reason, uncorrected CAT activities were expressed as a
percentage of control; minor variations in transfection efficiency
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180 kDa —
Fig. 2. Western immunoblot of total protein from cultured human fetal
kidney cells probed with the Santa Cruz anti-hEGFR antibody (1:200). A
single immunoreactive band (arrow) is detected at an apparent molecular
weight of 180 kDa.
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Fig. 3. In the reporter construct (PERCAT2),
the EGFR promoter (nucleotides —1100 to
—16) and an enhancer element are positioned
upstream of the CAT eDNA. The wild-type
WTI (—I—) isoform is subcloned into a CMV-
driven expression vector. Various deletion
mutants and the R394W Drash mutant bearing
an arginine to tryptophan substitution in the
third zinc finger are depicted. The alternatively
spliced WTI (+1+) isoform is also shown.
WT1(—/—), ig
Fig. 4. Representative experiment showing inhibition of PERCAT2 (4 ,zg
DNA/assay) activity in HEK293 cells co-transfected with various amounts
of WTI(—/—) expression vector (0 to 4 jig DNA/assay). Each bar = mean
and SEM of three determinations. Similar results were obtained in two
separate experiments.
(each done in triplicate).
When PERCAT2 (4 jig) was co-transfected into HEK293 cells
together with a WT1 deletion mutant (2 jig) lacking 127 amino
acids at its amino terminus (CMV/D1 —I—)or a WT1 mutant (2
jig) in which a stop codon has been inserted at nucleotide 725 of
the cDNA (CMV/Exl-4), CAT activity was similar to that in cells
transfected with PERCAT2 alone (98% and 113% of control,
respectively; Fig. 5). On the other hand, a WTI mutant (2 jig)
lacking amino acids 159-263 from the central part of the molecule
but with normal N-terminal and zinc-finger domains (CMV/D2
—1+), retained strong inhibitoiy activity (32% of control), similar
to 2 jig WT1(—/— (45% of control) or its various splicing isoforms
(+1+, and —/+; 40%, 44% and 53% of control, respectively;
Fig. 5).
To anticipate the possible impact of Denys-Drash mutations on
WTI regulation of EGFR in the developing glomerulus, we
performed similar transient transfection assays in HEK293 cells
using a WTI construct (2 jig plasmid DNAlassay) bearing an
arginine to tryptophan conversion (R394W) in its third zinc finger
Expression plasmid, 2 .tg/assay
Fig. 5. Inhibition of PERCAT2 (4 ug DNA/assay) activity in HEK293
cells co-transfected with various WTI expression plasmids (2 jig DNA!
assay). Abbreviations are: C, control (no WT1); (—/-), full-length WTI;
Dl, deletion mutant lacking 127 N-terminal amino acids; D2, deletion
mutant lacking amino acids 159 to 263; Exl-4, mutant producing WT1
truncated protein generated by insertion of a stop codon at nucleotide
725; DRASH, WTI construct hearing the most common (R to W)
mutation within the third zinc finger; (+1—), (—1+) and (+1+), alterna-
tively spliced WTI isoforms. Each bar represents the mean SEM of 4 to
10 determinations. CAT activity with DI and Exl-4 mutants were not
significantly different from controls; all other groups were significantly
inhibited (P < 0.01) (ANOVA followed by Duncan's multiple group
comparison).
(CMV/Drash) [1, 4]. PERCAT2 inhibition by the Denys-Drash
construct (43% of control) was not significantly different than that
of the wild-type WTI.
EGFR immunohistochemistry in Denys-Drash kidney
To detect aberrant EGFR expression in renal glomeruli and
Wilms tumour tissue in Denys-Drash syndrome, we performed
immunohistochemistry on sections of renal tissue obtained from
an affected three-year-old girl at the time of tumor resection.
Glomeruli exhibited typical mesangial sclerosis and showed no
evidence of epithelial cell proliferation. No immunoreactive
EGFR was detected in glomeruli (Fig. 6), tubules or in adjacent
tumour tissue (data not shown).
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DISCUSSION
During renal development, nephron formation occurs on an
individual basis. Consequently, localized control of the growth
factor systems that direct local cell division is required. We have
noted that immunoreactive human EGFR is found in the rapidly
expanding proximal and distal tubular segments of the nephron,
but not in visceral epithelial cells of the maturing glomerulus
(GVEC) nor in early mesenchymal condensates (Fig. 1). In
contrast, expression of WT1 is especially high in GVEC and
absent from maturing tubular segments (Fig. 1). This inverse
expression pattern is compatible with the hypothesis that EGFR
transcription is suppressed by WTI in the developing glomerulus.
Englert et al reported a somewhat different pattern of immu-
nodetectable EGFR involving "blastemal mesenchyme and S-
shaped bodies" in a 13-week human fetal kidney [4]. It is difficult
to comment on the minor discrepancies between our observations
and those of Englert et al, since the particular Oncogene Science
antibody used for their study was not described, and they did not
perform Western blotting or use a blocking peptide to demon-
strate specificity. With regard to the lack of EGFR expression in
fetal glomerular podocytes, our data are in agreement with those
of Englert et al [4].
The function of EGFR in the developing kidney is still unclear.
Kidney cell lines and primary human fetal kidney cells proliferate
in response to EGF or TGF-a in vitro; both TGF-a and high levels
of EGFR mRNA and peptide have been noted in developing
rodent and human kidney [6—8]. Transgenic mice homozygous for
disrupted EGFR genes rapidly develop uremia in postnatal life
and die within the first weeks of life with dilated medullary
collecting tubules, suggesting tubular dysfunction but without
marked derangement of renal anatomy [15]. Detailed measures of
tubule size or function have not yet been reported. Our observa-
tions are compatible with the view that EGFR may be involved in
elongation of maturing tubules, but is not critical to the early
stages of tubulogenesis in which nephron segmentation patterns
are established.
In co-transfection assays, activity of the human EGFR enhanc-
er/promoter-CAT reporter construct (PERCAT2) was markedly
inhibited by increasing amounts of CMV/WTI(—/—) expression
plasmid. This effect was specific since CMV/WT1(—/—) produced
no inhibition of a CM V/CAT reporter plasmid or f3-galactosidase
expression activity from plasmids driven by CMV, SV40 or RSV
promoters. CMV-based plasmids expressing WTI proteins lack-
ing the normal N-terminal domain (Dl) or zinc finger domains
(EX1-4) exhibited no inhibition of PERCAT2 activity, indicating
that both domains are essential for transcriptional repression. In
contrast, deletion of the middle portion of the WTI molecule
(D2) had no effect on its inhibitory activity.
Four isoforms of the WT1 protein have been identified in fetal
kidney. Each contains four zinc-finger domains encoded by exons
7 to 10 and may or may not include a 17-amino acid domain
encoded by exon 5 and a 3-amino acid insertion (KTS) between
zinc fingers 3 and 4 [10]. The four isoforms (—/—,
—/+, +/—,
+/+) are expressed in constant ratio during kidney development
and germline WTI mutations are associated with severe develop-
mental renal defects [3, 16]. Promoter sequences of certain
putative WTI gene targets such as retinoic acid receptor-a,
contain the EGRI recognition sequence (GCG GGG GCG)
shown to interact directly with zinc fingers 2 to 4 of the WTI
(—/—) protein, but not with isoforms bearing the +KTS insertion
(—/+ or +/+) [9]. On the other hand, other WT1-binding
sequences (TCC) have been described in growth factors impor-
tant for renal development (such as IGF-ll and PDGF-A chain
promoters) that interact with both the —/— and —/+ isoforms
[17—19]. Inspection of the EGFR promoter sequence shows both
an EGRI-like site [12, 13] and two TCC,, motifs; only the latter
were shown by Englert et alto form direct complexes with WTI
protein [4]. They also noted that endogenous EGFR expression in
U2OS cells was suppressed by the +/+ WTI isoform, though not
as powerfully as with WTI(—/--) [4]. Consistent with this, we
found that all WT1(—/—) (—/+) (+/—) and (+/+) isoforms were
able to inhibit PERCAT2 activity.
In patients with the Drash syndrome, germline WT1 mutations
deregulate normal differentiation of the glomerulus, causing
congenital massive proteinuria [2, 3, 16]. Surprisingly, an expres-
sion plasmid containing the most common Drash mutation (mis-
sense 1180C to T transition, converting 394arginine to tryptophan in
zinc finger 3) retained inhibitory activity when co-transfected with
PERCAT2. This result suggests that EGFR expression by GVEC
may be appropriately down-regulated in Drash patients. Accord-
ingly, GVEC proliferation is absent and no immunoreactive
EGFR was detectable in glomeruli, tubules or tumor tissue in our
Denys-Drash patient. We speculate that overexpression of EGFR
does not contribute to the abnormalities of glomerulogenesis or
the occurrence of Wilms tumours in Denys-Drash syndrome.
Presumably, the sclerotic changes seen in mesangial areas of the
glomerulus are due to dysregulation of other gene targets bearing
promoters with classical EGR1 sites which are sensitive to the
Denys-Drash mutation. For example, retinoic acid receptor-a
gene transcription is likely to be dysregulated in Denys-Drash
patients, since its promoter cannot bind mutant WT1 protein [9].
Recently, Van den Heuvel et al reported that glomerular chon-
droitin sulfate was selectively increased in the kidney from a
Denys-Drash patient [20]. Conceivably, the promoter for the core
peptide of this proteoglycan (normally synthesized by glomerular
epithelial cells) might be another candidate WT1 target which
would explain the accumulation of mesangial matrix in Denys-
Drash syndrome.
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APPENDIX
Abbreviations are: WT1, Wilms' tumor gene protein product; EGFR,
epidermal growth factor receptor; TGF-a, transforming growth factor-
alpha; GVEC, glomerular visceral epithelial cells; IGF-ll, insulin-like
growth factor-If; PDGF-A, platelet-derived growth factor A-chain; CAT,
chloramphenicol acetyltransferase.
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